



Microcaps appoints Dragan Grabulovski and Ronald Kogens as new members of the Board of Directors

- Dragan Grabulovski and Ronald Kogens have been elected to the Board of Directors of Microcaps, bringing extensive expertise in business development, startup financing, and legal matters
- The new board members join the Founders and Chairperson Hanne de Mora, an experienced entrepreneur and board member at Nestlé and Volvo Group

Zürich, 12.01.2021

Microcaps AG, a Zurich based company developing a new gold standard in microencapsulation, announced the appointment of Dr. Dragan Grabulovski and Ronald Kogens as independent members of the Board of Directors.

Dr. Dragan Grabulovski is the former co-founder and CSO of Covagen (acquired in 2014 by Johnson & Johnson). Since 2015, he has worked as a biotech consultant and serial entrepreneur.

Ronald Kogens is a partner and tech lawyer at Froriep, a Swiss based law firm. He specializes in VC-financing and financial market law with a focus on early-stage, disruptive technologies and life science.

Hanne de Mora, Chairwoman of the Board stated: "I am extremely happy with the newly appointed members, each of them possesses an expertise that will be essential as we continue to grow and penetrate the market with our proprietary microencapsulation platform. These are very exciting times to become involved with Microcaps."

Dr. Dragan Grabulovski states: "I am impressed by the versatility of Microcaps' technology, it is truly fascinating to explore the wide range of benefits Microcaps can bring, from injectable treatments, probiotic delivery, to flavor and fragrance delivery. I am thrilled to be part of this journey."



Ronald Kogens says: "I am very excited to join Microcaps and I look forward to contributing to the creation of a strong portfolio of products. Microcaps may introduce a paradigm shift in the way microcapsules are controlled, delivered and released throughout multiple industries."

About Microcaps:

Founded in early 2019, the ETH Zürich based tech startup Microcaps will bring Swiss precision to the world of microencapsulation. The company's unique and patented technology allows it to fabricate microcapsules at an unmatched precision and efficiency providing its customers with tailored microencapsulation solutions. The technology has its largest impact potential in the fields of pharmaceuticals, nutrition and cosmetics. For further information, please visit www.microcaps.ch

Contact:

Michael Hagander, co-CEO of Microcaps AG, michael.hagander@microcaps.ch